

Special Issue

New Therapeutic Advances in Rare Tumors

Message from the Guest Editor

Rare cancers are defined as those malignant tumors with an incidence less than 6 per 100,000 inhabitants and year. Using this definition, 22% of all cancer are considered rare cancers, that means, as a group, 108 new rare cancer cases per 100,000 and year.

Considering the prevalence, it is estimated that about 4,300,000 patients are living in the European Union with a diagnosis of rare cancer (24% of prevalence). Despite the fact that a substantial number of rare cancers have well characterized histomolecular entities, patients diagnosed with these rare cancers are disadvantaged compared to patients diagnosed with common cancers. The 5-year overall survival rates are 47% in rare cancer versus 65% in common cancers. This difference in survival expectation is multifactorial, difficulties or delay in correct diagnosis, limited access to centers with expertise or inadequate funding on research programs are among the reasons explaining this difference.

Guest Editor

Dr. Javier Martin-Broto

Hospital Universitario Virgen del Rocío, Sevilla, Spain

Deadline for manuscript submissions

closed (31 December 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/45241

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)